Objective: Although an increasing number of patients with peripheral arterial disease undergo multiple revascularization procedures, the effect of prior interventions on outcomes remains unclear. The purpose of this study was to evaluate perioperative outcomes of bypass surgery in patients with and those without prior ipsilateral treatment.
Peripheral arterial disease (PAD) affects 12% to 20% of people in the United States older than 60 years and is associated with substantial morbidity and mortality. 1 As the proportion of elderly patients as well as the utilization of endovascular procedures continues to increase, rates of reintervention for PAD have been steadily rising. 2, 3 Among patients undergoing lower extremity bypass surgery in the current era, it is estimated that 22% to 25% underwent prior ipsilateral endovascular interventions and 13% to 19% had prior ipsilateral open bypass. [4] [5] [6] Despite increased rates of reintervention, the impact of subsequent revascularization procedures has only recently been studied. Long-term outcomes comparing primary and secondary bypass have been reported with conflicting results. Several studies demonstrated worse outcomes in those patients undergoing secondary bypass, yet others found equivocal long-term outcomes in patients with prior endovascular interventions. [6] [7] [8] [9] [10] [11] [12] Interestingly, despite data on the long-term impact of secondary bypass, differences in perioperative outcomes remain unclear. Previous studies suggest that prior unsuccessful treatment is not associated with worse perioperative performance of bypass surgery. [9] [10] [11] [12] However, a study of 3504 patients undergoing bypass surgery, of which 33% were secondary bypass, found prior revascularization to be a risk factor for in-hospital return to the operating room and graft occlusion at discharge. 6 The body of literature on this topic is still limited; most recent studies included only single-institution data with small sample sizes and were unable to adjust for prior procedure type. Therefore, the purpose of this study was to assess perioperative outcomes in patients undergoing bypass surgery after prior ipsilateral bypass surgery or endovascular intervention using a large national representative clinical registry.
METHODS
Data source. Data were obtained from the prospectively collected Targeted Vascular module of the American College of Surgeons National Surgical Quality Improvement Program (NSQIP). NSQIP is a national, multi-institutional, quality improvement initiative of academic and community-based centers that provides 30-day outcomes in an effort to improve overall patient care. Standardized definitions capture demographics, comorbidities, intraoperative variables, and 30-day postoperative outcomes in a randomly selected subset of patients at each participating institution. The Targeted Vascular module includes additional disease-and procedure-specific characteristics as well as procedurerelated outcomes chosen by vascular surgeons. Trained clinical reviewers identify potential procedures by reviewing operative case logs, then collect data and categorize procedures using Current Procedural Terminology (CPT) codes at both the targeted and nontargeted NSQIP. To ensure data quality, NSQIP data collection is validated by rigorous audits as well as by comprehensive studies. [13] [14] [15] Further details on the NSQIP and the Targeted Vascular module are available at https://www.facs.org/quality-programs/acs-nsqip. This study was approved by the Beth Israel Deaconess Medical Center Institutional Review Board, and informed consent was waived because of the deidentified nature of this registry.
Patients. All patients undergoing a nonemergent infrainguinal bypass between 2011 and 2014 were included. Patients were stratified by symptom status: intermittent claudication vs chronic limb-threatening ischemia (CLTI). Those without documented symptom status and asymptomatic patients were excluded (n ¼ 313 [4.1%]). Secondary bypass was defined as a new bypass with a prior endovascular intervention or bypass treating the same ipsilateral arteries as in the current procedure. Additional procedural detail from previous interventions was not captured by NSQIP, which subsequently did not allow us to determine the timing or indication of the prior procedure. Patients without any history of ipsilateral revascularization procedures were designated as undergoing primary bypass. Baseline and intraoperative characteristics as well as 30-day postoperative outcomes were compared between patients undergoing primary and secondary bypass. In a subgroup analysis among patients undergoing secondary bypass, results were stratified according to the type of prior ipsilateral procedures (endovascular vs bypass).
Clinical and outcome variables. Baseline characteristics included demographics, comorbidities, and preprocedural medication. Age was evaluated as a continuous variable; however, all patients 90 years of age or older are recorded as 90þ by NSQIP to prevent identification of individual patients. Antiplatelet medication preoperatively was considered when one of the following agents was documented: aspirin, clopidogrel, eptifibatide, or aspirindipyridamole (Aggrenox Purposeful selection of covariates was performed to populate the multivariable models, with a cutoff point of P # .1 for inclusion of covariates on univariate screen. 17 Separate models were constructed for each perioperative outcome. All tests were two sided, and a value of P < .05 was considered significant. Statistical analysis was performed using SPSS Statistics 23 (IBM Corp, Armonk, NY).
RESULTS
A total of 7302 patients were included, with 4540 (62%) undergoing primary bypass (68% of these were performed for CLTI) and 2762 (38%) undergoing secondary bypass (74% for CLTI). Among patients undergoing secondary bypass, 1536 (56%) had prior ipsilateral bypass (75% for CLTI) and 1226 (44%) had prior ipsilateral endovascular intervention (72% for CLTI).
Baseline characteristics
Baseline characteristics are detailed in Table I . Compared with CLTI patients undergoing primary bypass, those undergoing secondary bypass were younger (67.6 vs 68.8 years; P < .001), were more likely to be white (68% vs 61%; P < .001), and less frequently had tissue loss (51% vs 63%; P < .001). In terms of comorbidities, CLTI patients with prior revascularization had less renal insufficiency (23% vs 28%; P < .001) and were less often on dialysis preoperatively (6% vs 9.1%; P < .001). Finally, secondary bypass patients were more likely to be treated with an antiplatelet agent (87% vs 76%; P < .001) or statin preoperatively (74% vs 67%; P < .001). Among patients with claudication, demographics and comorbidities were similar. However, patients with prior revascularization were more likely to be treated with an antiplatelet agent (88% vs 81%; P < .001) or statin preoperatively (77% vs 67%; P < .001).
Operative details
Operative details are listed in Table II . Secondary bypass was associated with a significantly longer procedure time compared with primary bypass in patients with CLTI (240 vs 223 minutes; P < .001). Among patients with CLTI undergoing secondary bypass, saphenous vein conduits were less frequently used (54% vs 64%; P < .001) and prosthetic or spliced/composite vein conduits were more commonly used (46% vs 36%; P < .001). In addition, femoral-tibial/pedal bypass procedures were performed more often in CLTI patients with prior revascularization (39% vs 32%; P < .001), whereas femoropopliteal bypass (51% vs 56%; P < .001) and popliteal-tibial/pedal bypass (9.9% vs 12%; P < .01) were less common in those undergoing secondary bypass. Concurrent suprainguinal procedures were evenly distributed between primary and secondary bypass. Similar to patients with CLTI, those with claudication undergoing secondary bypass had longer procedure times (207 vs 187 minutes; P < .001) and were less frequently revascularized with a saphenous vein conduit (53% vs 59%; P ¼ .02) and more often with prosthetic or spliced/composite vein conduits (47% vs 41%; P ¼ .02). Finally, those undergoing a second revascularization were more likely to have a femoral-tibial/pedal bypass (22% vs 14%; P < .001) and less likely to undergo a femoropopliteal bypass (72% vs 81%; P < .001).
Postoperative outcomes
Among CLTI patients undergoing secondary compared with primary bypass, similar rates of 30-day mortality were observed (1.7% vs 2.2%; P ¼ .22; Table III) . Secondary bypass was associated with various adverse events, including MALE (9.8% vs 7.4%; P < .01), major reintervention (6.5% vs 4.7%; P < .01), bleeding leading to transfusion or secondary procedure (22% vs 18%; P < .001), wound infection (9.5% vs 7.8%; P ¼ .04), and untreated loss of patency (3.6% vs 2.1%; P < .01). In addition, CLTI patients with prior revascularization were more likely to be discharged to home (72% vs 67%; P < .001).
Among claudication patients, 30-day mortality did not differ between secondary and primary bypass (0.4% vs 0.6%; P ¼ .76). Patients with prior revascularization had significantly more MALE (5.2% vs 2.5%; P < .01), major reintervention (4.4% vs 2.2%; P < .01), bleeding leading to transfusion or secondary procedure (12% vs 6.7%; P < .001), unplanned reoperation (9.8% vs 6.9%; P ¼ .02), and longer hospital stay (4 days vs 3 days; P < .01).
In a subgroup analysis of secondary bypass patients, we compared outcomes of those with prior bypass and those with prior endovascular intervention. Among CLTI patients with prior bypass, there was a trend toward lower mortality, although significance was not achieved (1.2% vs 2.3%; P ¼ .07). Similarly, no difference in mortality was observed in patients with claudication between prior bypass and endovascular intervention (0.8% vs 0%; P ¼ .25). Prior endovascular intervention was associated with more wound infections for CLTI (12% vs 7.8%; P < .001) and claudication patients (9.1% vs 5.4%; P ¼ .049). In addition, revascularization with saphenous vein conduits was more common in patients with prior endovascular intervention compared with those with prior bypass in CLTI (64% vs 45%; P < .001) and claudication (58% vs 49%; P ¼ .01). Patients with CLTI and a prior bypass had higher rates of MALE (11% vs 8%; P ¼ .02) and major reintervention (7.8% vs 4.9%; P < .01) and were more likely to be discharged to home (75% vs 68%; P < .01) than those with prior endovascular intervention. Untreated loss of patency occurred more frequently in patients undergoing secondary bypass after prior bypass with CLTI (4.4% vs 2.6%; P ¼ .03) and claudication (2.6% vs 0.6%; P ¼ .04) compared with those with prior endovascular intervention.
Reoperations and readmissions
Unplanned reoperations were more common in patients undergoing secondary compared with primary bypass for both CLTI (15% vs 13%; P ¼ .01) and claudication (9% vs 5.6%; P < .01; Table IV ). Unplanned reoperations were primarily limb related, with more open and endovascular revascularizations in CLTI patients undergoing secondary bypass (7.1% vs 4.7%; P ¼ .001), whereas major and minor amputations were higher in those undergoing bypass with prior endovascular intervention (4.9% vs 3.0%; P ¼ .04). There was no significant difference in reoperation rates of claudication patients with a prior bypass and a prior endovascular intervention.
Comparable rates of unplanned readmissions were observed between primary and secondary bypass for CLTI (13% vs 14%; P ¼ .25) and claudication (7.6% vs 8.7%; P ¼ .38; Table V ). In addition, the most common reason for readmission was infection in patients with CLTI (55%) and claudication (54%).
Multivariable analysis
Primary vs secondary bypass. In adjusted analysis (Table VI) , secondary bypass was found to be an independent predictor of MALE for both CLTI (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.1-1.7) and claudication patients (OR, 2.1; 95% CI, 1.3-3.5). Prior Prior bypass surgery vs prior endovascular intervention. To assess associations with adverse events and prior procedure type, an additional subgroup analysis in the secondary bypass cohort was performed. Among patients undergoing secondary bypass for CLTI, prior bypass was associated with MALE (OR, 1.4; 95% CI, 1.03-1.9) and major reintervention (OR, 1.5; 95% CI, 1.03-2.2) compared with prior endovascular intervention. After adjustment for several covariates (eg, graft type, diabetes, tissue loss), CLTI patients with a prior bypass had a decreased risk of wound infection (OR, 0.6; 95% 
DISCUSSION
This study demonstrates increased risk of adverse perioperative outcomes in patients undergoing a secondary bypass compared with primary bypass. Patients undergoing secondary bypass for CLTI or claudication were at increased risk of 30-day MALE, major reintervention, and unplanned reoperation. Subgroup analysis found that secondary bypass with prior endovascular intervention was a prominent predictor of wound infections, whereas 30-day major reintervention was more commonly performed following bypass after prior bypass.
In 2005, the randomized Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL) trial compared endovascular-first and bypass-first strategies in limb ischemia patients and found similar morbidity and mortality rates up to 2 years after surgery. 18 Although the BASIL trial has been criticized for multiple shortcomings in study design, further analysis demonstrated that bypass surgery was associated with decreased mortality from 2 years onward compared with endovascular intervention alone (hazard ratio, 0.61; 95% CI, 0.50-0.75). 19 Therefore, current American College of Cardiology/American Heart Association guidelines recommend that bypass surgery be preferentially performed over endovascular intervention in CLTI patients with a life expectancy of >2 years. 20 Nonetheless, a bypass-first approach is not widely accepted as the optimal treatment option, and results of the Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial are still pending. 21 In addition, many institutions have adopted an endovascular-first approach in PAD patients because it is less invasive and therefore associated with less perioperative risk, although perioperative mortality is similar. Because management of PAD does not end with the first intervention in many cases, several studies were undertaken to assess whether failed initial treatment affects the outcome of subsequent revascularization. [6] [7] [8] [9] [10] [11] [12] In the BASIL trial, further analysis showed that patients undergoing a secondary bypass with prior endovascular intervention had a notable 1-year failure rate (defined as death, major amputation, recurrent symptoms, or reintervention) of 54% compared with 70% in the bypass group with prior bypass. 22 In 2011, Nolan et al studied the Vascular Study Group of New England database and demonstrated that for 1880 bypass surgeries performed for CLTI, both prior endovascular intervention and prior bypass surgery were independently associated with 1-year amputation and graft occlusion. 9 However, there were no demonstrable differences in 30-day outcomes. Subsequently, Jones et al studied an expanded cohort of 3504 patients undergoing bypass surgery from the Vascular Study Group of New England and, using inverse probability-weighted analyses, demonstrated inferior 1-year outcomes associated with secondary compared with primary bypass in CLTI patients, including MALE-free survival (55% vs 63%; P < .01) and reintervention or amputation-free survival (53% vs 60%; P < .01). 6 Interestingly, adverse events following secondary bypass were not affected by the type of primary treatment, either endovascular or bypass. In the perioperative period, patients undergoing secondary bypass were also more likely to return to the operating room for graft thrombosis during their index hospitalization and more frequently had graft occlusion at discharge. Despite these findings, no differences were found for secondary bypass patients with regard to other major in-hospital adverse events, including mortality, myocardial infarction, and ipsilateral amputation, regardless of indication. In accordance with these findings, our data also indicated that patients undergoing secondary bypass more often had 30-day adverse limb events, with both ipsilateral major amputation and reintervention as driving factors in CLTI patients, whereas major reintervention alone was the primary driver in those with claudication. Several other studies reported short-term outcomes. In comparison to primary bypass treatment, Uhl et al found no association between prior endovascular intervention and 30-day mortality, graft failure, or major amputation.
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In addition, Santo et al determined that prior endovascular intervention was not associated with 30-day mortality or myocardial infarction and was not a predictor for overall wound complication compared with primary bypass. 12 Although we showed similar short-term mortality rates, our data indicated that prior endovascular intervention was associated with a 1.5-fold increased risk of wound infection compared with primary treatment as well as secondary bypass following prior bypass surgery after adjusting for multiple confounders such as graft type, diabetes, and tissue loss. The published rate of surgical site infections after bypass has varied, with a reported incidence of 5% to 23%; however, no recent studies identified prior revascularization as a risk factor. 18, 23, 24 This could be related to the more frequent use of saphenous veins as conduits compared with prosthetic or arm veins and the increased likelihood of wound infections associated with ipsilateral autogenous vein harvesting. However, we still observed an increased risk of wound infections in comparing prior endovascular intervention with primary bypass, although the proportion of revascularization with saphenous vein conduits between these groups was similar. Unmeasured confounding variables, such as ipsilateral vs contralateral vein harvest, length and number of incisions, and basilic/cephalic vs saphenous vein conduits, may have an impact on this study and cannot be accounted for. In addition, the type and number of previous endovascular interventions were unfortunately not captured by NSQIP and could therefore not be evaluated to better answer why prior endovascular intervention patients were at increased risk for wound infections. The increased risks of adverse events following secondary revascularization may be explained by a more aggressive disease process. Patients who have already suffered failure of a primary procedure are likely to represent a selected group that is at greater general risk for treatment failure and other adverse outcomes. In addition, because of unfavorable anatomy and hampered inflow or runoff vessels caused by previous procedures, these patients may be predisposed to an increased risk of complication. We attempted to account for this with multivariable modeling; however, unmeasured indicators of more aggressive disease phenotype cannot be controlled for. This study does not attempt to shed light on the optimal primary treatment strategy, nor does it answer which secondary treatment strategy is superior. However, there are important clinical implications to this study. First, these short-term outcomes may provide clinicians valuable guidance in the selection and counseling of PAD patients. Furthermore, physicians should factor in the significant association of failed prior ipsilateral treatment with future interventions and recognize inferior outcomes of repeated procedures.
This study has several limitations. First, NSQIP has potential errors in coding and misreporting of data. Second, the lesion severity characteristics and extent of PAD as well as explicit detail of the timing and procedural information from patients' previous interventions are not available in this clinical registry. Prior procedures were taken directly from the patients' medical records by clinical reviewers; however, with these strict variable definitions, we were unable to identify patients with both a prior endovascular and surgical revascularization. We believe that these patients were most likely coded as having had a prior bypass rather than a prior endovascular intervention, which should be factored in when considering these study results. This would most likely bias our outcomes toward the null, and thus we think that the observed differences are likely to be real and perhaps underestimated. The importance of disease severity and type of prior procedure, particularly single or multilevel treatment and placement of stents, has been confirmed in previous studies, 25 ,26 but NSQIP variables lack this level of granularity. The clinical registry also lacks detail on incision type, graft configuration (in situ vs transposed/reversed anatomically tunneled graft), and severity of tissue loss (ulcers vs gangrene), all of which could have added further detail to our comparison. However, the strength of NSQIP is the large sample size and its national representation. Although we could determine that primary treatment failure is associated with worsened outcomes of secondary bypass, we cannot establish causation, given the retrospective nature of the study design. Finally, NSQIP captures follow-up data only up to 30 days. Therefore, we were unable to determine long-term outcomes, such as graft patency and amputation-free survival, in those patients with prior revascularization.
CONCLUSIONS
This study demonstrates that bypass surgery following prior ipsilateral revascularization is associated with increased 30-day MALE in both CLTI and claudication patients. Other adverse events included major reintervention, bleeding leading to transfusion or secondary procedure, and unplanned reoperation. Furthermore, this study shows that the type of prior procedure is associated with outcomes of secondary bypass. In particular, prior endovascular intervention proved an important predictor for wound infections, and prior bypass was associated with MALE and major reintervention. The present findings should be considered in the selection of patients and during operative planning, particularly because the proportion of patients undergoing multiple revascularization procedures is rising. 
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